In Vivo Evaluation Of Bispecific T-Cell Engager Efficacy & Safety

Advantages of Evaluating Immunomodulatory Therapeutics In Vivo in Hu-PBMC NSG Mice to Investigate GVHD

You save (%)

Select Options

Oncology JAX Preclinical Models and Services

You save (%)

Select Options

CD34+ Hu-NSG-SGM3-IL15 Tech Sheet

You save (%)

Select Options

ActionSeq 2.0

You save (%)

Select Options

Comprehensive Immunodeficient Suite

You save (%)

Select Options

A New Way to Study Cytokine Release Syndrome

You save (%)

Select Options

Syngeneic Tumor Studies

You save (%)

Select Options

A New MHC Class I & II Deficient Platform Humanized With PBMC Has Delayed Xenogeneic GvHD

You save (%)

Select Options